Jack Kelly

Jack Kelly began their career in 2012 as a Cell Culture Co-op at Acceleron Pharma. In 2013, they joined Pfizer as a Research Assistant. From 2016 to 2020, they were a DPhil Candidate at the University of Oxford with the Structural Genomics Consortium. In 2020, they became a Senior Scientist and Scientist at Sai Life Sciences Ltd, where they engaged worldwide clients to address drug discovery research needs and performed SAR using multiple biochemical assays. In 2021, they joined Casma Therapeutics as a Scientist II, SPR & Biophysics, where they lead biophysics and structural biology structure-activity relationship efforts to drive hit-to-lead progression in early-stage drug discovery programs and manages CRO partnerships across a broad range of biochemical and biophysical techniques.

Jack Kelly completed a Bachelor of Science (B.S.) in Biology, General from Northeastern University in 2014, having started in 2010. Jack then went on to pursue a Doctor of Philosophy (Ph.D.) in Clinical Medicine from the University of Oxford, which they completed in 2020.